- $661.84m
- $661.81m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | 5.72% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +50.73 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Veraxa Biotech AG is a Switzerland-based company. The Company is primary engaged in biotechnology, advancing innovations in the field of antibody development and microfluidic technologies. The Company’s activities center on participating in and supporting businesses engaged in the screening of diagnostic and therapeutic antibodies, as well as their chemical or recombinant modification, formatting, validation, and preclinical and clinical development. In addition, the Company is involved in the commercialization and marketing of such solutions both domestically and internationally. The Company operates mainly through investments and strategic management of affiliated entities, providing services and oversight to companies within its portfolio.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- June 25th, 2025
- Public Since
- August 9th, 2024
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 147,732,813
- Address
- Talacker 35, ZUERICH, 8001
- Web
- Phone
- Auditors
- WithumSmith Brown PC
Latest News for VRXA
Upcoming Events for VRXA
Q2 2026 Voyager Acquisition Corp Earnings Release
Q3 2026 Voyager Acquisition Corp Earnings Release
Similar to VRXA
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
As of Today at 23:59 UTC, shares in Veraxa Biotech AG are trading at . This share price information is delayed by 15 minutes.
Shares in Veraxa Biotech AG last closed at and the price had moved by -56.8% over the past 365 days. In terms of relative price strength the Veraxa Biotech AG share price has underperformed the S&P500 Index by -65.63% over the past year.
There is no consensus recommendation for this security.
Find out moreVeraxa Biotech AG does not currently pay a dividend.
Veraxa Biotech AG does not currently pay a dividend.
Veraxa Biotech AG does not currently pay a dividend.
To buy shares in Veraxa Biotech AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of , shares in Veraxa Biotech AG had a market capitalisation of $661.84m.
Here are the trading details for Veraxa Biotech AG:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: VRXA
Based on an overall assessment of its quality, value and momentum Veraxa Biotech AG is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Veraxa Biotech AG. Over the past six months, its share price has underperformed the S&P500 Index by -61.13%.
As of the last closing price of , shares in Veraxa Biotech AG were trading -59.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Veraxa Biotech AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at .
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Veraxa Biotech AG's directors